BioLineRx Corp (BLRX) - Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan

The BioLineRx Ltd. (BLRX) business model is based on the promotion of Aphexda, with the primary growth drivers being the reach of transplant centers and trials for the treatment of pancreatic tumors. The product's integration into hematological practice accelerates stem cell collection, establishing the method as an industry standard. The market trend reflects an EV/EBITDA value of 0.00. Stable management is successfully expanding insurance reimbursements in the US, strengthening shareholder confidence.

BLRX BioLineRx Ltd: Nilai perusahaan marang bathi operasional sadurunge panyusutan ing interval 23.11.2025 - 10.11.2026

BLRX (biolinerx.com): rincian analitis lan laporan miturut indikator

- rega saham lan target rega konsensus:

Kutipan saham BioLineRx Corp|BLRX - Konsensus nilai wajar

- indikator kapitalisasi pasar:

Nilai pasar BioLineRx Corporation|BLRX - Total Nilai Perusahaan

- indikator nilai buku ekuitas:

Aset Bersih saben Siji Saham BioLineRx|BLRX - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku biolinerx.com|BLRX - Gunggung Aset Perusahaan

- data utang lan likuiditas:

- data bathi bisnis lan rasio investasi:

BLRX - Penghasilan resik perusahaan|Bathi mangsa ngarep BioLineRx Ltd.|BLRX - Nilai perusahaan marang bathi resik|Prakiraan rega marang bathi BioLineRx Ltd.|BLRX - Rasio nilai perusahaan marang wutah bathi|Pangali EV/EBITDA BioLineRx Corporation|BLRX - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) BioLineRx|BLRX - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan biolinerx.com|BLRX - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep BioLineRx Ltd.

Ringkesan analitik perusahaan:BLRX (BioLineRx Corp)

Fundamental asset screening requires analyzing business value relative to its ability to generate earnings before interest, taxes, depreciation, and amortization. An EV/EBITDA multiple valuation compares the total capitalization of BioLineRx Ltd. (BLRX) with its operating cash flow, where stable figures confirm the company's resilience amid the commercialization of its stem cell drug and the minimization of liquidity risks.

Analisis pesaing